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Background: After a phase I trial of accelerated, twice daily high dose 
radiotherapy showing good tolerability, a prospective study relating 
primary tumor size with radiation dose in non-operated patients with 
NSCLC was started.
Methods: 01/2004 - 12/2006: 79 patients with 81 histologically / cy-
tologically proven NSCLC tumors. Stage I: 19 pts., II: 4 pts., IIIA: 31 
pts., IIIB: 25 pts. Weight loss >5% in the past 3 months: 20 patients. 
Slow planning CTs (4sec./slice), patients freely breathing, 7 mm 
margins GTV to PTV, target splitting technique. 4 groups with primary 
tumor sizes (mean number of 3 perpendicular diameters) <2,5; 2,5-4,5; 
4,5-6,0; >6,0 cm (11/41/22/7 pts., respectively); tumor dose 73,8; 79,2; 
84,6; 90,0 Gy (ICRU), respectively; single dose 1,8 Gy; twice daily, 
interval 11h; 5 days/week; duration 33 days median (29-42). Nodes 
61,2 Gy (54,0-75,6 Gy), nodes electively 45,0 Gy (to volume about 6 
cm cranial to macroscopically involved nodes). 
In 62 patients chemotherapy before RT was given, 2 cycles median (1-
10); no concurrent chemotherapy.
Median follow-up of patients alive: 16,1 months (4,2-40,1).
Results: Until now 10 local failures (0/11, 3/41, 5/22, 2/7 in the respec-
tive groups) and 2 regional failures, resulting in an actuarial local and 
regional tumor control of 77% and 96% at 2 years, respectively.
Overall actuarial 1-, 2-year survival rate for all patients: 75%, 55%, 
respectively, median 24,8 months. Median survival time for 28 patients 
IIIA-N2: 30,1 months.
2 patients suffered treatment-related letal acute toxicity: pulmonary ﬁ-
brosis 5 and 6 months after the end of radiotherapy. In the pretherapeu-
tic CT scans of both patients clear signs of existing pulmonary ﬁbrosis 
were visible. Furthermore no patient with acute pulmonary toxicity 
>grade 2. Acute esophagitis grade 3: 3 pts; grade 2: 4 pts.; grade1: 22 
pts. No chronic toxicity >grade1.
Conclusions: Local and regional tumor control rates are high. Nodes 
need smaller doses than primary tumors. Survival (considering a quar-
ter of the patients having unfavourable prognostic features) is good. 
Patients with preexisting pulmonary ﬁbrosis must be excluded from 
accelerated, twice daily applied high dose radiotherapy. Recruitment of 
patients to the study is continued.
P3-048 NT: Radiation Posters, Wed, Sept 5 – Thur, Sept 6 
Development of respiratory sensor system for the respiratory 
guided radiotherapy
Yoon, Jai-Woong Suh, Tae-Suk 
Dept. of Biomedical Engineering, College of Medicine, The Catholic 
University of Korea, Seoul, Korea
Background: The respiratory signal acquisition should be reliable for 
the gated radiotherapy. The spirometer has a direct correlation with a 
lung volume change but is susceptible to a signal drift. On the other 
hand, the surface displacement measurement is convenient and drift 
free but its amplitude can be affected by daily marker setup. In this 
work, a stable spirometer system was developed for the gated radio-
therapy and the correlation to an organ motion was obtained compared 
to that of a custom-made stereo camera system.
Methods: Tidal volume measurements were performed on a spirometer 
ampliﬁer and a ﬂow head. Spirometer calibration was performed using 
a 3L calibration syringe to convert the reading value from voltage to 
ﬂow rate and correct for different ﬂow sensitivity. A tidal volume signal 
was produced by integrating ﬂow rate by time. The volume baseline 
was determined in real time using the random sample consensus 
(RANSAC) algorithm to exclude the irregular breathing points. A skin 
surface marker was monitored by a stereo vision system. The marker 
imaging was performed at two IEEE-1394 cameras. The stereo-image 
pair of marker was acquired synchronously and the 3-D position was 
determined using the triangulation algorithm. Skin surface displace-
ment measurements were compared to the tidal volume signal for com-
parison. The ﬂuoroscopic image of lung tumor patients was correlated 
to the surrogate marker signals. 
Results: Respiratory signal was acquired and displayed by the 
developed software. The volume drift correction ensured the stable 
acquisition of respiratory signal which allowed for gating the linear 
accelerator. The stereo camera system could track the 3-D position of 
skin markers with an accuracy of 2 mm. The comparison of the two 
surrogate marker signals represented some phase delay and indicated 
that the spirometry had a better correlation with a real tumor motion 
than the surface displacement measurements.
Conclusions: The respiratory signal acquisition system was developed 
using the spirometer and the stereo-vision camera for gated radiothera-
py. Stable spirometry volume signal could be attained for the amplitude 
gating by applying the user-deﬁned correction algorithm. The devel-
oped system was useful to investigate the accuracy of surrogate marker 
signals and their correlation to a real tumor motion.
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Purpose: To evaluate the treatment outcomes of body-frame based 
fractionated stereotactic radiosurgery (SRS) on consecutive days for 
stage I non-small cell lung cancer (NSCLC).
Materials: Between Jun 1999 to Feb 2006, 34 patients diagnosed as 
stage I, T1N0 or T2N0, resectable NSCLC were treated with body-
frame based fractionated SRS. The reasons of curative SRS were 
variable. Twenty-ﬁve patients had several medical problems conﬂicting 
surgical procedure and the other nine patients refused surgery although 
they could be a surgical candidate. To obtain higher tumor dose and 
better dose conformation with less normal tissue toxicity, we used 
fractionated stereotactic radiosurgery (SRS) on consecutive 3-4 days. 
Doses of 10-20 Gy per fraction were delivered to the clinical target vol-
ume (CTV) up to a total dose of 30-60 Gy with three to four fractions 
on consecutive days.
Results: Ten patients (29.4%) showed a complete response, 19 (55.9%) 
a partial response, and 5 patients (14.7%) showed stable disease, result-
ing in a total response rate of 85.3%. One patient (4%) showed progres-
sive disease 1 month after SRS. The overall local progression free 
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survival (LPFS) rate was 75.8% at median follow-up of 19 months, and 
1- and 2-year LPFS was 93.8%, 73.2% respectively. Overall survival 
was relatively worse, 90.8% at 1 year and 51.9% at 2 year, because 
most of patients had a medical problem in lung or heart. While all pa-
tients developed grade 1 radiation pneumonitis within 3 months of SRS 
treatment, none developed symptomatic or serious late complications.
Conclusions: The results demonstrate that fractionated SRS on con-
secutive days was both effective and convenient for treating technically 
operable, but medically inoperable patients with early stage NSCLC. 
This treatment appears to offer comparable local disease control with-
out serious complications.
Novel Therapeutics: Surgery: RFA Etc.
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Introduction: The surgical treatment of pulmonary metastases is a pro-
cedure of proved therapeutic effectiveness, with a 5 years survival rate 
ranging from 20 to 40%. In the last years we proposed, as an alternative 
approach, radiofrequency thermal ablation of pulmonary metastases to 
patients not considered surgical candidates.
Materials and Methods: From 1990 to the 2006 we performed 138 
surgical resection in 118 patients with pulmonary metastases ( 20 pa-
tients were operated two times). The range of the disease free interval 
between the presentation of the primary tumor and that of metastases 
(DFI) was of 28,68 months (range 0-19 years). The patient’s age range 
was 21-80 years (average 50,1). We removed 219 metastases (average 
1,58; range: 1-7), all conﬁrmed by hystological examination. The size 
of the lesions ranged from 1 to 8 cm, (average 2,58 cm). The average 
hospital stay was 8,1 days (range 6-24); we estimated also the post-op-
erative pain and the complication rate (25 cases, 18.1% respectively). 
We did not observe any intra-operating mortality. From 2003 to 2005 
24 patients ( average age 69,5 years, range 66-75 years) with pulmo-
nary metastases (maximum diameter 3,5 cm.) not considered surgical 
candidates, underwent CT guided percutaneous radiofrequency thermal 
ablation (RF). All these patients underwent a CT/PET examination 
pre-treatment, repeated within 24h from the thermoablation in one day-
surgery. 
Results: The DFI was of 8,74 months (range 0-27 months), while aver-
age survival after surgical resection was of 24,37 months (range 2-10 
years). Until today 30 patients are alive, with an average follow-up of 
65,8 months (range 12 months-15 years); only one patient had disease 
recurrence. The 1 year survival rate was 76.2%, the 3 years 44.1%, the 
5 years 28.3% and the 10 years 16,2%. We considered several prognos-
tic factors: hystology, DFI, number of metastases, number of resec-
tions, lesion mono/bilaterality, type of resection and the diameter of the 
metastases. The data regarding patients treated with RF are preliminary. 
The treatment in 100% of the cases was feasible and safe, with no sig-
niﬁcant morbidity or mortality. The six months survival rate was 100%, 
the 1 year 75% and the 3 year 12,5%. The use of the CT/PET fusion 
imaging after the procedure always evidenced the absence of metabolic 
activity in the treated metastatic lesion. 
Conclusions: The surgery of the pulmonary metastases is today a valid 
procedure for patients at M1 stage with good general and respira-
tory conditions and with an effective control of primary tumor. The 
percutaneous radiofrequency thermal ablation could be an important 
alternative for the treatment of pulmonary metastases in patients not 
considered to be surgical candidates.
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Purposes: The aim of this study was to evaluate the diagnostic efﬁcacy 
of positron emission tomography (PET)/computed tomography (CT) in 
the detection of residual tumor after cryoablation of pulmonary tumors 
regardless of primary or metastatic lesions. 
Materials and Methods: Eight patients with 10 lesions (mean size: 
4.9 cm) were evaluated in this study. Total 25 procedures of cryoabla-
tion were preformed and 23 PET/CT examinations (including pre and 
post ablation) were analyzed. The patients had PET/CT before and after 
ablation using [18F]-2-ﬂuoro-2-deoxy-D-glucose. CT images were 
interpreted, not correlated with the results of PET-CT scan. PET-CT im-
ages were also evaluated and measured SUV (1hr, 2hr, retention index 
were acquired. We acquired the percent change of SUV according to 
the following equation; RI (Retention Index) = (SUV 1h-SUV2h)x100/
SUV 1h The accuracy for detection of residual tumor by the different 
imaging modalities following ablation was assessed.
Results: Eight patients with a mean age of 64.8 (range 52-73) years 
were reviewed. The histopathology was primary lung cancers (8, 
squamous -6, adenocarcinoma -2, metastatic cancers (2, from rectum 
and trachea). The mean follow-up period was 194 days. Two patients 
had residual tumor after ablation, six patients were revealed near total 
cavitation developed and no evidence of hypermetabolic foci in the 
cavitary lesion on 2nd follow up PET/CT The above ﬁnding were cor-
related with enhancing solid component on enhanced CT scan within 2 
weeks of PET-CT scan. The difference of the HU between pre and post 
CE study were correlated with SUV (standardized uptake value) for the 
target lesion on PET-CT.
Conclusion: PET-CT has potential roles in the evaluation for the 
residual viable tumors after cryoablation and has been proved to be 
superior to CT alone when assessing the pulmonary malignant lesions 
after cryoablation.
